Monte Rosa Therapeutics, Inc. (GLUE)
10.30
-0.02
(-0.19%)
USD |
NASDAQ |
Oct 09, 16:00
10.30
0.00 (0.00%)
After-Hours: 20:00
Monte Rosa Therapeutics Enterprise Value : 294.71M for Oct. 9, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 09, 2026 | 294.71M |
| October 08, 2026 | 296.42M |
| October 07, 2026 | 283.64M |
| October 06, 2026 | 258.07M |
| October 05, 2026 | 292.16M |
| October 02, 2026 | 311.76M |
| October 01, 2026 | 376.53M |
| September 30, 2026 | 433.63M |
| September 29, 2026 | 417.44M |
| September 28, 2026 | 414.88M |
| September 25, 2026 | 420.00M |
| September 24, 2026 | 415.74M |
| September 23, 2026 | 430.22M |
| September 22, 2026 | 490.74M |
| September 21, 2026 | 461.76M |
| September 18, 2026 | 450.68M |
| September 17, 2026 | 490.74M |
| September 16, 2026 | 495.00M |
| September 15, 2026 | 523.97M |
| September 14, 2026 | 601.53M |
| September 11, 2026 | 616.02M |
| September 10, 2026 | 637.32M |
| September 09, 2026 | 632.21M |
| September 08, 2026 | 633.06M |
| September 04, 2026 | 596.42M |
| Date | Value |
|---|---|
| September 03, 2026 | 642.44M |
| September 02, 2026 | 628.80M |
| September 01, 2026 | 636.47M |
| August 31, 2026 | 604.94M |
| August 28, 2026 | 557.21M |
| August 27, 2026 | 637.32M |
| August 26, 2026 | 642.44M |
| August 25, 2026 | 657.78M |
| August 24, 2026 | 590.88M |
| August 21, 2026 | 635.62M |
| August 20, 2026 | 676.53M |
| August 19, 2026 | 760.90M |
| August 18, 2026 | 697.84M |
| August 17, 2026 | 727.66M |
| August 14, 2026 | 737.89M |
| August 13, 2026 | 766.87M |
| August 12, 2026 | 776.24M |
| August 11, 2026 | 760.05M |
| August 10, 2026 | 765.16M |
| August 07, 2026 | 770.28M |
| August 06, 2026 | 755.79M |
| August 05, 2026 | 747.27M |
| August 04, 2026 | 787.32M |
| August 03, 2026 | 727.66M |
| July 31, 2026 | 824.82M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| United Therapeutics Corp. | 20.77B |
| ACADIA Pharmaceuticals, Inc. | 2.522B |
| Alnylam Pharmaceuticals, Inc. | 30.80B |
| Anika Therapeutics, Inc. | 248.88M |
| Savara, Inc. | 867.94M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -43.40M |
| Revenue (Quarterly) | 8.968M |
| Total Expenses (Quarterly) | 52.36M |
| EPS Diluted (Quarterly) | -0.4276 |
| Gross Profit Margin (Quarterly) | 78.69% |
| Profit Margin (Quarterly) | -483.9% |
| Earnings Yield | -18.50% |
| Normalized Earnings Yield | -18.50 |